Author

Kazem Behbehanil

Post doc University of Bern - Cited by 420 - AAV gene therapy

Biography

Professor Kazem Behbehani (OBE), is currently the Director-General of the Dasman Diabetes Institute an affiliate of the Kuwait Foundation for the Advancement of Science's (KFAS) in Kuwait. During his career he assumed numerous eminent international and regional positions. His international experience includes various programs, contributions and participation in different countries for diverse fields of study. His research interests reflect his wide range of publications in various national and international journals. 
Title
Cited by
Year
HDAC1 regulates fear extinction in mice
S Bahari-Javan, A Maddalena, C Kerimoglu, J Wittnam, T Held, M Bähr, ...Journal of Neuroscience 32 (15), 5062-5073, 2012201
202
2012
Triple vectors expand AAV transfer capacity in the retina
A Maddalena, P Tornabene, P Tiberi, R Minopoli, A Manfredi, M Mutarelli, ...Molecular Therapy 26 (2), 524-541, 2018201
100
2018
Adeno-associated virus-mediated, mifepristone-regulated transgene expression in the brain
A Maddalena, J Tereshchenko, M Bähr, S KüglerMolecular Therapy-Nucleic Acids 2, 2013201
36
2013
High-throughput screening identifies kinase inhibitors that increase dual AAV vectors transduction in vitro and in mouse retina.
A Maddalena, F Dell’Aquila, P Giovannelli, P Tiberi, L Wanderlingh, ...HUMAN GENE THERAPY, 20820
1
2018
500. Triple AAV Vectors Expand AAV Cargo Capacity in the Retina
A Maddalena, P Colella, I Trapani, R Minopoli, A AuricchioMolecular Therapy 23, S200, 20520
1
2015

Referred From: https://scholar.google.com/citations?user=-s5FUFEAAAAJ&hl=en

Cited by
Citations 420
h-index 5
i10-index 4
Recommended Journals
Open Access Journals